Browse the corpus

REFERENCES Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97:3. Magill AJ, Reed SG. American Trypanosomiasis. In: Hunter's Tropical Medicine and Emerging Deseases, 8th ed, Strickland GT (Ed), W.B. Saunders Company, Philadelphia 2000. p.653. Rassi, A, Ferreira, HO. Tentativas de tratamento especifico da fase aguda da doença de Chagas com nifurtimox em esquema de duraçao prolongada. Rev Soc Bras Med Trop 1971; 5:235. Boainain, E. Tratamento etiologico da doença de Chagas na fase cro. Rev Goiania Med 1979; 25:1. Camandaroba EL, Reis EA, Gonçalves MS, et al. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 2003; 36:201. Veloso VM, Carneiro CM, Toledo MJ, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz 2001; 96:1005. Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res 1986; 19:19. Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat Res 1989; 224:263. Teixeira AR, Córdoba JC, Souto Maior I, Solórzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg 1990; 43:146. Teixeira AR, Silva R, Cunha Neto E, et al. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes. J Comp Pathol 1990; 103:37. Kirchhoff LV. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am 1993; 7:487. Bocchi EA, Higuchi ML, Vieira ML, et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Lung Transplant 1998; 17:399. US Pharmacopeial Convention. Benznidazole. US Pharmacopeia Monographs: US Pharmacopeial Convention, 1995. US Pharmacopeial Convention. Nifurtimox. US Pharmacopeia Monographs: US Pharmacopeial Convention, 1995. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.

US Pharmacopeial Convention. Nifurtimox. US Pharmacopeia Monographs: US Pharmacopeial Convention, 1995. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635. Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 2009; 3:e484. Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54:2979. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55. Pinazo MJ, Espinosa G, Gállego M, et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010; 82:583. Drugs for Neglected Disease Initiative. Chagas disease: DNDi Strategy, 2010. file://www.treatchagas.org/rd_dndi_strategy.aspx (Accessed on March 10, 2010). Urbina JA. New advances in the management of a long-neglected disease. Clin Infect Dis 2009; 49:1685. Topic 14004 Version 5.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1002-115.25.216.6-2088D0F3A9-S244013.14]